The effects of RelB deficiency on lymphocyte development and function

Journal of Autoimmunity

Volumn 65, Issue , 2015, Pages 90-100

  Sharfe, Nigel ^a   Merico, Daniele ^b   Karanxha, Ariana ^a   Macdonald, Carly ^a   Dadi, Harjit ^a   Ngan, Bo ^a   Herbrick, Jo Anne ^b   Roifman, Chaim M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Autoimmunity; Lymphocyte; NF B; RelB; Rheumatoid arthritis

Indexed keywords

B CELL ACTIVATING FACTOR; CD27 ANTIGEN; CD40 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 6; L SELECTIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR RELB; NFKB1 PROTEIN, HUMAN; RELB PROTEIN, HUMAN;

ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL EXPANSION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DYSPLASIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; LEUKOCYTE COUNT; LYMPHOCYTE FUNCTION; MALE; MEDICAL RECORD REVIEW; MEMORY CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RELB DEFICIENCY; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS; ABNORMALITIES; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; INFANT; NEWBORN; PATHOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; T LYMPHOCYTE SUBPOPULATION;

AUTOIMMUNITY; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD, PRESCHOOL; HUMANS; INFANT; INFANT, NEWBORN; INTERLEUKIN-2; MALE; NF-KAPPA B P50 SUBUNIT; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; THYMUS GLAND; TRANSCRIPTION FACTOR RELB;

EID: 84941695123     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.09.001     Document Type: Article

References (55)

1. Millet P., McCall C., Yoza B. RelB: an outlier in leukocyte biology. J. Leukoc. Biol. 2013, 94:941-951.
2. Sun X.H., Kincade P.W. Gatekeeper mechanisms for immature B cells. Nat. Immunol. 2002, 3:898-899.
3. Sun S.C. Non-canonical NF-kappaB signaling pathway. Cell Res. 2011, 21:71-85.
4. Orange J.S., Jain A., Ballas Z.K., Schneider L.C., Geha R.S., Bonilla F.A. The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J. Allergy Clin. Immunol. 2004, 113:725-733.
5. Courtois G., Smahi A., Reichenbach J., Doffinger R., Cancrini C., Bonnet M., et al. A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 2003, 112:1108-1115.
6. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. Nat. Genet. 2001, 27:277-285.
7. Janssen R., van Wengen A., Hoeve M.A., ten Dam M., van der Burg M., van Dongen J., et al. The same IkappaBalpha mutation in two related individuals leads to completely different clinical syndromes. J. Exp. Med. 2004, 200:559-568.
8. Lopez-Granados E., Keenan J.E., Kinney M.C., Leo H., Jain N., Ma C.A., et al. A novel mutation in NFKBIA/IKBA results in a degradation-resistant N-truncated protein and is associated with ectodermal dysplasia with immunodeficiency. Hum. Mutat. 2008, 29:861-868.
9. Picard C., Casanova J.L., Puel A. Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IkappaBalpha deficiency. Clin. Microbiol. Rev. 2011, 24:490-497.
10. Pannicke U., Baumann B., Fuchs S., Henneke P., Rensing-Ehl A., Rizzi M., et al. Deficiency of innate and acquired immunity caused by an IKBKB mutation. N. Engl. J. Med. 2013, 369:2504-2514.
11. Schimke L.F., Rieber N., Rylaarsdam S., Cabral-Marques O., Hubbard N., Puel A., et al. A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy. J. Clin. Immunol. 2013, 33:1088-1099.
12. Chen K., Coonrod E.M., Kumánovics A., Franks Z.F., Durtschi J.D., Margraf R.L., et al. Germline mutations in NFKB2 implicate the noncanonical NF-κB pathway in the pathogenesis of common variable immunodeficiency. Am. J. Hum. Genet. 2013, 93:812-824.
13. Lee C.E., Fulcher D.A., Whittle B., Chand R., Fewings N., Field M., et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood 2014, 124:2964-2972.
14. Liu Y., Hanson S., Gurugama P., Jones A., Clark B., Ibrahim M.A. Novel NFKB2 mutation in early-onset CVID. J. Clin. Immunol. 2014, 34:686-690.
15. Lhtela J., Nousiainen H.O., Stefanovic V., Tallila J., Viskari H., Karikoski R., et al. Mutant CHUK and severe fetal encasement malformation. N. Engl. J. Med. 2010, 363:1631-1637.
16. Chen K., Coonrod E.M., Kumanovics A., Franks Z.F., Durtschi J.D., Margraf R.L., et al. Germline mutations in NFKB2 implicate the noncanonical NF-kappaB pathway in the pathogenesis of common variable immunodeficiency. Am. J. Hum. Genet. 2013, 93:812-824.
17. Lee C.E., Fulcher D.A., Whittle B., Chand R., Fewings N., Field M., et al. Autosomal-dominant B-cell deficiency with alopecia due to a muation in NFKB2 that results in nonprocessable p100. Immunobiol. 2014, 124:2964-2972.
18. Tucker E., O'Donnell K., Fuchsberger M., Hilton A.A., Metcalf D., Greig K., et al. A novel mutation in the Nfkb2 gene generates an NF-κB2 "Super Repressor". J. Immunol. 2007, 179:7514-7522.
19. Lindsley A.W., Qian Y., Valencia C.A., Shah K., Zhang K., Assa'ad A. Combined immune deficiency in a patient with a novel NFKB2 mutation. J. Clin. Immunol. 2014, 34:910-915.
20. Brue T., Quentien M.H., Khetchoumian K., Bensa M., Capo-Chichi J.M., Delemer B., et al. Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. BMC Med. Genet. 2014, 15:139-145.
21. Oeckinghaus A., Hayden M.S., Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12:695-708.
22. Burkly L., Hession C., Ogata L., Reilly C., Marconi L.A., Olson D., et al. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 1995, 373:531-536.
23. Weih F., Carrasco D., Durham S.K., Barton D.S., Rizzo C.A., Ryseck R.P., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995, 80:331-340.
24. Merico D., Sharfe N., Hu P., Herbrick J.-A., Roifman C.M. RelB deficiency causes combined Immunodeficiency. LymphoSign J. 2015, 2:147-155.
25. Roifman C.M., Somech R., Kavadas F., Pires L., Nahum A., Dalal I., et al. Defining combined immunodeficiency. J. Allergy Clin. Immunol. 2012, 130:177-183.
26. Shearer W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., et al. Lymphocyte subset in healthy children from birth through 18 years of age: the PEDIATRIC AIDS Clinical Trials Group P1009 study. J. Allergy Clin. Immunol. 2003, 112:973-980.
27. Reem G.H., Yeh N.H. Interleukin 2 regulates expression of its receptor and synthesis of gamma interferon by human T lymphocytes. Science 1984, 225:429-430.
28. Yamada T., Mitani T., Yorita K., Uchida D., Matsushima A., Iwamasa K., et al. Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase. J. Immunol. 2000, 165:804-812.
29. Kontgen F., Grumont R.J., Strasser A., Metcalf D., Li R., Tarlinton D., et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995, 9:1965-1977.
30. Liou H.C., Jin Z., Tumang J., Andjelic S., Smith K.A., Liou M.L. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int. Immunol. 1999, 11:361-371.
31. Boomer J.S., Green J.M. An enigmatic tail of CD28 signaling. Cold Spring Harb. Perspect. Biol. 2010, (2):a002436.
32. Takeda K., Harada Y., Watanabe R., Inutake Y., Ogawa S., Onuki K., et al. CD28 stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-Grb2/Gads axis. Int. Immunol. 2008, 20:1507-1515.
33. Marienfeld R., Berberich-Siebelt F., Berberich I., Denk A., Serfling E., Neumann M. Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control. Oncogene 2001, 20:8142-8147.
34. Hailfinger S., Nogai H., Pelzer C., Jaworski M., Cabalzar K., Charton J.E., et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14596-14601.
35. Piatosa B., Wolska-Kuśnierz B., Pac M., Siewiera K., Gałkowska E., Bernatowska E. B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood. Cytom. B Clin. Cytom. 2010, 78:372-381.
36. Morbach H., Eichhorn E.M., Liese J.G., Girschick H.J. Reference values for B cell subpopulations from infancy to adulthood. Clin. Exp. Immunol. 2010, 162:271-279.
37. Harada K., Ohira S., Isse K., Ozaki S., Zen Y., Sato Y., et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab. Invest. 2003, 83:1657-1667.
38. Yoza B.K., Hu J.Y., Cousart S.L., Forrest L.M., McCall C.E. Induction of RelB participates in endotoxin tolerance. J. Immunol. 2006, 177:4080-4085.
39. Chen X., Yoza B.K., El Gazzar M., Hu J.Y., Cousart S.L., McCall C.E. RelB sustains IkappaBalpha expression during endotoxin tolerance. Clin. Vacc. Immunol. 2009, 16:104-110.
40. Jenkinson W.E., McCarthy N.I., Dutton E.E., Cowan J.E., Parnell S.M., White A.J., et al. Natural Th17 cells are critically regulated by functional medullary thymic microenvironments. J. Autoimmun. 2015, 63:13-22. 10.1016/j.jaut.2015.06.008.
41. Coquet J.M., Ribot J.C., Babała N., Middendorp S., van der Horst G., Xiao Y., et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J. Exp. Med. 2013, 210:715-728.
42. Ishimaru N., Kishimoto H., Hayashi Y., Sprent J. Regulation of naive T cell function by the NF-kappaB2 pathway. Nat. Immunol. 2006, 7:763-772.
43. Nepom G.T. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. Adv. Ommunol. 1998, 68:315-332.
44. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005, 52:3433-3438.
45. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678. Wellcome Trust Case Control Consortium.
46. Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3168-3171.
47. Aoki C.A., Roifman C.M., Lian Z.X., Bowlus C.L., Norman G.L., Shoenfeld Y., et al. IL-2 receptor alpha deficiency and features of primary biliary cirrhosis. J. Autoimmun. 2006, 27:50-53.
48. Cohen S., Dadi H., Shaoul E., Sharfe N., Roifman C.M. Cloning and characterization of a lymphoid-specific inducible human protein tyrosine phosphatase, Lyp. Blood 1999, 93:2013-2024.
49. Bottini N., Vang T., Cucca F., Mustelin T. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 2006, 18:207-213.
50. Wu J., Katrekar A., Honigberg L.A., Smith A.M., Conn M.T., Tang J., et al. Identification of substrates of human protein-tyrosine phosphatase PTPN22. J. Biol. Chem. 2006, 281:11002-11010.
51. Feitsma A.L., Toes R.E., Begovich A.B., Chokkalingam A.P., de Vries R.R., Huizinga T.W., et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients. Rheumatol. Oxf. 2007, 46:1092-1095.
52. Burkhardt H., Hüffmeier U., Spriewald B., Böhm B., Rau R., Kallert S., et al. Association between protein tyrosine phosphatase 22 variant R620W in conjunction with the HLA-DRB1 shared epitope and humoral autoimmunity to an immunodominant epitope of cartilage-specific type II collagen in early rheumatoid arthritis. Arthritis Rheum. 2006, 54:82-89.
53. Gough S.C., Walker L.S., Sansom D.M. CTLA4 gene polymorphism and autoimmunity. Immunol. Rev. 2005, 204:102-115.
54. Wagner U.G., Koetz K., Weyand C.M., Goronzy J.J. Perturbation of the T cell repertoire in rheumatoid arthritis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14447-14452.
55. Yudoh K., Matsuno H., Nakazawa F., Yonezawa T., Kimura T. Reduced expression of the regulatory CD4+ T cell subset is related to Th1/Th2 balance and disease severity in rheumatoid arthritis. Arthritis Rheum. 2000, 43:617-627.